P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Must have received: proteasome inhibitor

Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor

Must have received: immunomodulatory agent

Must have relapsed / refractory MM, having received treatment with...immunomodulatory agent (IMiD)

Must have received: anti-CD38 therapy

Must have relapsed / refractory MM, having received treatment with...anti-CD38 therapy

Cannot have received: allogeneic cellular therapy

Has received prior allogeneic cellular therapy or gene therapy

Cannot have received: gene therapy

Has received prior allogeneic cellular therapy or gene therapy

Cannot have received: allogeneic stem cell transplantation

Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant

Cannot have received: autologous stem cell transplantation

Exception: within 90 days

has undergone autologous transplantation within 90 days

Cannot have received: anti-cancer medications

Exception: within 2 weeks of the time of initiating conditioning LD therapy

Has received anti-cancer medications within 2 weeks of the time of initiating conditioning LD therapy

Cannot have received: monoclonal antibody therapy

Exception: within 4 weeks of initiating conditioning LD therapy

Has received monoclonal antibody therapy within 4 weeks of initiating conditioning LD therapy

Cannot have received: immunosuppressive medications

Exception: within 2 weeks of the time of administration of P-BCMA-ALLO1, and/or expected to require them while on study

Has received immunosuppressive medications within 2 weeks of the time of administration of P-BCMA-ALLO1, and/or expected to require them while on study

Cannot have received: systemic corticosteroid therapy

Exception: within 1 week or 5 half-lives (whichever is shorter) of the administration of P-BCMA-ALLO1 or is expected to require it during the course of the study

Has received systemic corticosteroid therapy within 1 week or 5 half-lives (whichever is shorter) of the administration of P-BCMA-ALLO1 or is expected to require it during the course of the study

Cannot have received: radiation therapy

Exception: within 1 week of initiating conditioning LD therapy

Has received radiation within 1 week of initiating conditioning LD therapy

Cannot have received: live vaccine

Exception: within the last 28 days prior to administration of LD therapy

Administration of a live vaccine within the last 28 days prior to administration of LD therapy